Revolutionizing Pharmaceutical Financial Analysis
The pharmaceutical industry faces ongoing challenges as the average drug development cost has increased by 15%, to now exceed $2 billion among leading biopharma companies. The industry grapples with rapid, complex drug launches, increased competition, and delayed ROI, with about half of the leading companies missing their earnings guidance this year. These challenges highlight the need for precise financial forecasting, strategic data-driven decisions, and a comprehensive understanding of market views on individual drugs.
In this eBook, we tackle two essential questions:
- How do financial analysts navigate biopharma regulations, clinical trial approval processes, and dense competitive landscapes?
- How can tools like Visible Alpha BioPharma be leveraged to access detailed drug metadata and financial insights to enhance strategic decision-making in the biotech and pharmaceutical industries?
Unlock the Power of Forecast Data
Visible Alpha Insights captures the forecasts, assumptions and logic from full working sell-side models and integrates them into comparable views across analysts, companies and peer groups. This deep consensus data provides a quick understanding of the sell-side view on a company or industry at a level of granularity, timeliness and interactivity that has never before been possible.
250+
Contributing Brokers
17,000+
Companies in Broker Coverage
7,000+
Companies in Consensus
1M+
Total Consensus Line Items